Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 2
2006 1
2007 3
2009 2
2010 5
2011 2
2012 5
2013 2
2014 6
2015 11
2016 8
2017 4
2018 7
2019 1
2020 5
2021 7
2022 9
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, Lucchetti J, Giordano G, Pretta A, Tamburini E, Pirrone C, Rapposelli IG, Diana A, Martinelli E, Garajová I, Simionato F, Schirripa M, Formica V, Vivaldi C, Caliman E, Rizzato MD, Zanuso V, Nichetti F, Angotti L, Landriscina M, Scartozzi M, Ramundo M, Pastorino A, Daniele B, Cornara N, Persano M, Gusmaroli E, Cerantola R, Salani F, Ratti F, Aldrighetti L, Cascinu S, Rimassa L, Antonuzzo L, Casadei-Gardini A. Rimini M, et al. Among authors: formica v. Liver Int. 2023 Aug;43(8):1803-1812. doi: 10.1111/liv.15641. Liver Int. 2023. PMID: 37452505
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.
Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Boccaccino A, Morano F, Brugia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Randon G, Murgioni S, Borelli B, Buonadonna A, Giordano M, Fontanini G, Conca V, Formica V, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C. Rossini D, et al. Among authors: formica v. J Clin Oncol. 2022 Sep 1;40(25):2878-2888. doi: 10.1200/JCO.22.00839. Epub 2022 Jun 6. J Clin Oncol. 2022. PMID: 35666229 Free PMC article. Clinical Trial.
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.
Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, Frassineti GL, Boscolo G, Cinieri S, Di Donato S, Pella N, Bergamo F, Raimondi A, Arnoldi E, Antonuzzo L, Granetto C, Zustovich F, Ronzoni M, Leo S, Morano F, Loupakis F, Buggin F, Zagonel V, Fassan M, Cremolini C, Boni L, Pietrantonio F; GONO Foundation Investigators. Lonardi S, et al. Among authors: formica v. J Clin Oncol. 2023 Dec 1;41(34):5263-5273. doi: 10.1200/JCO.23.00506. Epub 2023 Aug 3. J Clin Oncol. 2023. PMID: 37535876 Clinical Trial.
Gender Differences in Cancer-associated Venous Thromboembolism.
Riondino S, Guadagni F, Formica V, Ferroni P, Roselli M. Riondino S, et al. Among authors: formica v. Curr Med Chem. 2017;24(24):2589-2601. doi: 10.2174/0929867323666161018144505. Curr Med Chem. 2017. PMID: 27758714 Review.
HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling.
Formica V, Riondino S, Morelli C, Guerriero S, D'Amore F, Di Grazia A, Del Vecchio Blanco G, Sica G, Arkenau HT, Monteleone G, Roselli M. Formica V, et al. Br J Cancer. 2023 Aug;129(2):222-236. doi: 10.1038/s41416-023-02266-2. Epub 2023 Apr 20. Br J Cancer. 2023. PMID: 37081189 Free PMC article. Review.
Irinotecan or Oxaliplatin: Which is the First Move for the Mate?
Morelli C, Formica V, Riondino S, Russo A, Ferroni P, Guadagni F, Roselli M. Morelli C, et al. Among authors: formica v. Curr Med Chem. 2021;28(16):3158-3172. doi: 10.2174/0929867327666201016124950. Curr Med Chem. 2021. PMID: 33069191 Review.
CD26: a multi-purpose pharmacological target.
Vincenzo F, Manfredi T, Carmine C, Mario R. Vincenzo F, et al. Curr Clin Pharmacol. 2014 May;9(2):157-64. doi: 10.2174/1574884708666131111201654. Curr Clin Pharmacol. 2014. PMID: 24219003 Review.
Issues and promises of bevacizumab in prostate cancer treatment.
Cereda V, Formica V, Roselli M. Cereda V, et al. Among authors: formica v. Expert Opin Biol Ther. 2018 Jun;18(6):707-717. doi: 10.1080/14712598.2018.1479737. Epub 2018 May 30. Expert Opin Biol Ther. 2018. PMID: 29781343 Review.
87 results